Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial

• 資料種別: 記事
• タイトル: Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial
• 著者標目: Neeraj Agarwal; Arun A Azad; https://orcid.org/0000-0001-7350-5622; Joan Carles; Andre P Fay; Nobuaki Matsubara; Daniel Heinrich; Cezary Szczylik; Ugo De Giorgi; Jae Young Joung; Peter C C Fong; Eric Voog; Robert J Jones; Neal D Shore; Curtis Dunshee; Stefanie Zschäbitz; Jan Oldenburg; Xun Lin; Cynthia G Healy; Nicola Di Santo; Fabian Zohren; Karim Fizazi
• 出版年月日等: 2023-07
• 出版年（W3CDTF）: 2023-07
• タイトル（掲載誌）: The Lancet
• 巻号年月日等（掲載誌）: 402 10398
• 掲載巻: 402
• 掲載号: 10398
• 掲載ページ: 291-303
• 掲載年月日（W3CDTF）: 2023-07
• ISSN（掲載誌）: 01406736
• 出版事項（掲載誌）: Elsevier BV
• 対象利用者: 一般
• DOI: 10.1016/s0140-6736(23)01055-3
• 作成日（W3CDTF）: 2023-06-04
• 著作権情報: https://www.elsevier.com/tdm/userlicense/1.0/; https://www.elsevier.com/legal/tdmrep-license; http://www.elsevier.com/open-access/userlicense/1.0/; https://doi.org/10.15223/policy-017; https://doi.org/10.15223/policy-037; https://doi.org/10.15223/policy-012; https://doi.org/10.15223/policy-029; https://doi.org/10.15223/policy-004
• 関連情報（URI）: https://api.elsevier.com/content/article/PII:S0140673623010553?httpAccept=text/xml; https://api.elsevier.com/content/article/PII:S0140673623010553?httpAccept=text/plain
• 参照: Molecular Mechanisms of Prostate Cancer Development in the Precision Medicine Era: A Comprehensive Review; https://cir.nii.ac.jp/crid/1360302865737850496
• 連携機関・データベース: 国立情報学研究所 : CiNii Research; https://cir.nii.ac.jp/
• 提供元機関・データベース: Crossref; https://www.crossref.org